
Cordio Medical
Overview: Cordio Medical
The first application for this easy to use, medical-grade technology is for detection of congestive heart failure (CHF). Here, the HearO™ evaluates simple phrases in a patient’s speech and can determine, based on a pre-recorded baseline created by each patient, whether there is fluid accumulation in the patient's lungs, a sign related to CHF. With this information, the app alerts healthcare professionals who then decide if immediate or extra medical care is required.
The HearO™ can be used both as an early warning system of a worsening condition and as a method to reduce the need for extra hospitalizations by flagging deteriorating states that can be treated in a timely manner before they turn into more critical situations.
The details here are based on information received from, and verified solely by, the company.
Co Investors
Cordio Medical Management Team
Tamir Tal
CEO
Tamir joins Cordio Medical with over 20 years experience in operations, finance, business development and management of multiple high-tech companies. Tamir started his career as a corporate lawyer with Shiboleth LLP where he focused on hi-tech sector securities transactions, IPO, M&A and venture capital investments. He later served as COO at Neovasc Medical Ltd., a cardiovascular medical device company that developed the Neovasc Reducer™ for the treatment of refractory angina (NASDAQ: (NVCN) as well as COO at of Geomage a leading provider of imaging solution for the oil and gas industry. Since 2005, Tamir has held the position of Venture Partner at Peregrine Ventures.
Prof. Ilan Shallom
CTO
For more than 35 years Ilan has been at the forefront of speech signal processing and was an essential figure in developing numerous successful applications both for military intelligence and commercial markets. In 1985, Ilan joined DSP and served as the Director of the Speech Processing Group and led a large team of engineers to develop and implement DSP’s speech recognition products worldwide. In 1993, Ilan founded NSC, a global company that developed and sold speech recognition products for telephony networks. The company was later acquired by AudioCodes (NASDAQ: (AUDC). Ilan holds a PhD in Electrical and Computer Engineering from Ben-Gurion University.
LinkedIn profileProf. Chaim Lotan
CMO
Prof. Lotan has served as Director of Interventional Cardiology at Hadassah Medical Center, has as the Director of the Hadassah Heart Institute since September 2000 and Head of the Cardiovascular Division since 2015. He is a Professor of Medicine in Cardiology at The Hebrew University, and in 2004, he established the Hadassah Cardiovascular Research Center. Prof. Lotan founded the Israeli Working Group for Interventional Cardiology in Israel and served as its Secretary General for 4 years. He served as President of the Israel Heart Society in 2011-2013. He is the chairman of the Committee for Certification & Licensing of Coronary Stents in the Israel Ministry of Health. He has, in addition, participated in various research projects and initiated and directed many study protocols, and continues to do so. He also serves as a consultant to several startup companies. He is Course Co-Director of the international scientific congress “Innovations in Cardiovascular Interventions (ICI)” held in Israel. Prof. Lotan completed his medical training in Medicine and Cardiology at the Hadassah-Hebrew University Medical Center.
LinkedIn profileRonit Aviv
SVP
Ronit has over two decades of experience in Clinical Trials, both in the scientific side and in operations. Early in her career, she served as Head of the Clinical Department of two large international pharmaceutical companies, MSD and Actelion. During her career she served as Director & Clinical Leader in Teva R&D department. Ronit joined Cordio Medical in 2018 as a Sr VP Clinical, QA and RA. Ronit holds a PhD in Life Sciences from Tel-Aviv University.
LinkedIn profileItai Katsir
VP R&D
Itai has 15 year of experience in research, algorithm development and speech processing. Itai previously served as Director of Algorithms for Agrint, a start-up developing sensors for tree pest detection. Prior to Agrint, Itai was a Team Leader of Media Technology and Signal Processing at AudioCodes, leading research and development in the fields of automatic speech recognition, VoIP, and speech quality analysis and monitoring. In 2018, Itai joined Cordio Medical as VP R&D, leading and conducting algorithm research and development from POC to product. Itai holds a BSc. (Cum Laude) in Electrical engineering from BGU and an MSc. In Electrical engineering from Technion.
LinkedIn profileLeon Eting
VP Product
Leon brings with him more than 25 years’ experience in the high-tech industry with a focus on speech processing technologies. Prior to Cordio Medical, Mr. Eting served as Director Business Development VAS at Audiocodes. Mr. Eting also served as the CEO and Founder of HOTAS, a start-up company that developed, manufactured and sold voice activated wireless communication products for the automotive market. Mr. Eting was a fighter pilot in the Israeli Air Force. He holds a B.Sc. in Physics and Computer Science from Bar-Ilan University, Israel, and an MBA from INSEAD Business School (Fontainebleau, France).
LinkedIn profileProf. Offer Amir
Medical Director
Prof. Offer Amir, FACC, FESC. is the Director of the Heart Institute at Hadassah Medical Center, Jerusalem; Professor of Cardiovascular Medicine at the Hebrew University; and President of the Israel Heart Society.
Lior Klain
Head of Development
Lior has over 20 years of experience in leading and managing full-stack R&D groups of SaaS products. Lior brings with him extensive experience in implementing cutting edge R&D processes, back-end technologies, large scale systems, system architecture, as well as data science and algorithms development leadership. Lior started his career as a software developer in the elite IDF technology unit (MAMRAM) where he focused on developing C&C systems. Following his work for the IDF, he served as R&D Team Leader at c-nario, a startup that developed video technologies and content management systems. Lior held various senior management positions for global companies such as Voyager Analytics, Welltika, and NICE.
At a Glance: Cordio Medical
Cordio Medical provides medical grade, groundbreaking solutions to monitor several health conditions by analyzing voice samples recorded in a simple smartphone app backed by sophisticated and proprietary algorithms allowing near real-time monitoring and early detection of condition deterioration.
BEYOND WORDS
Using only patient speech, sampled via mobile device, the Cordio HearO™ can sense fluid accumulation related to congestive heart failure (CHF) and alert healthcare professionals in real time. This is the only non-invasive, easy to use medical grade, CHF monitoring device that offers patients and caretakers peace of mind and a true sense of control.
During monitoring, samples of the patient’s speech are analyzed and compared to Cordio Medical’s proven baseline created on a per patient basis, measuring specific differences which may signal a risk to the patient’s health. Once identified, HCPs are immediately informed, and life-saving measures can be taken in real time.
The HearO™ uses the patient’s speech to create a patient-specific and adaptive model, detecting differences which are characteristic of the target disorder and can lead to hospitalization or deterioration. Ultimately, the HearO™ can significantly reduce the need for additional hospitalization due to complications of CHF that can be remedied if addressed in a timely manner.
Information sourced from www.cordio-med.com ,verified solely by the company.